The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIceCure Medical Ltd. (Nasdaq: ICCM) announced positive top-line results from its ICESECRET clinical trial evaluating its ProSense cryoablation technology. The study demonstrated an 89.4% recurrence-free rate for patients with kidney tumors measuring 3 cm or less and no prior history of the disease. Across the general study population, the recurrence-free rate stood at 83.9% after a median follow-up period of 4 years. These findings highlight the efficacy of cryoablation as a viable, minimally invasive alternative to traditional surgical removal for small renal masses. Management expects the data to drive broader commercial adoption of ProSense in key markets, including the United States and Europe. The successful clinical outcome marks a significant milestone for the medtech firm as it seeks to expand its oncology treatment portfolio.